TrialCompass TCL

Find your clinical trial.

TrialCompass is a free tool to help patients, caregivers, and clinicians find and understand clinical trials for T-cell lymphoma. Use the filters on the left to find trials that match your situation.

For informational purposes only. Always discuss options with your healthcare team.

189

Curated Trials

14

Subtypes Covered

Updated June 2026

Live data

New here? Start by selecting your diagnosis on the left.

Browse a few featured trials

These are highest-priority Phase 3 trials currently recruiting. Apply filters on the left for a personalized list.

Phase 3RecruitingPriority 1 · Highest priorityNCT07300514

Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma

This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with a type of T-cell lymphoma called AITL. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who it's for

  • Age 18 Years or older
  • Newly diagnosed, not yet treated

Location

No US sites currently

Sponsor

Fudan University

Treatment length

Ask the trial team for details

Full detailsClinicalTrials.gov
Phase 3RecruitingPriority 1 · Highest priorityNCT06561048

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

This Phase 3 trial is comparing Soquelitinib, Belinostat, and other medications against other options for people whose a type of T-cell lymphoma called AITL has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is widely available at 21 US locations.

Who it's for

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment

Location

21 US sites · California, Connecticut, Florida +14

Sponsor

Corvus Pharmaceuticals, Inc.

Treatment length

Ask the trial team for details

Full detailsClinicalTrials.gov
Phase 3RecruitingPriority 1 · Highest priorityNCT06724237

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with a type of T-cell lymphoma called AITL. Patients are randomly assigned to different treatment groups to see which approach works best. It is widely available at 158 US locations.

Who it's for

  • Age 18 Years to 75 Years years
  • Newly diagnosed, not yet treated

Location

158 US sites · Alabama, Alaska, Arizona +27

Sponsor

Eastern Cooperative Oncology Group

Treatment length

Ask the trial team for details

Full detailsClinicalTrials.gov